Merck halts vorapaxar Phase III trial in ACS patients, amends TRA-2P Phase III trial
This article was originally published in Scrip
Executive Summary
Merck has announced major changes to two Phase III clinical studies of vorapaxar, an investigational cardiovascular focused therapeutic candidate that it acquired through the acquisition of Schering-Plough, following a review by a combined data safety and monitoring board. As a result of the safety and efficacy review, the company is discontinuing the TRACER study in patients with acute coronary syndrome (ACS) while the TRA-2P study, which is evaluating the compound in secondary prevention of heart attacks will only continue in a narrower patient population.